ID   S52A3_HUMAN             Reviewed;         469 AA.
AC   Q9NQ40; A0A2I6BQ49; A8K6P1; K0A6P4; Q5W1A0; Q5W1A1; Q8NCL7; Q96GD5;
DT   10-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 4.
DT   28-JUN-2023, entry version 168.
DE   RecName: Full=Solute carrier family 52, riboflavin transporter, member 3;
DE   AltName: Full=Riboflavin transporter 2;
DE            Short=hRFT2;
GN   Name=SLC52A3; Synonyms=C20orf54, RFT2, RFVT3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000312|EMBL:AUI80409.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND SUBCELLULAR LOCATION
RP   (ISOFORMS 1 AND 2).
RX   PubMed=29428966; DOI=10.1007/s00018-018-2757-4;
RA   Long L., Pang X.X., Lei F., Zhang J.S., Wang W., Liao L.D., Xu X.E.,
RA   He J.Z., Wu J.Y., Wu Z.Y., Wang L.D., Lin D.C., Li E.M., Xu L.Y.;
RT   "SLC52A3 expression is activated by NF-kappaB p65/Rel-B and serves as a
RT   prognostic biomarker in esophageal cancer.";
RL   Cell. Mol. Life Sci. 75:2643-2661(2018).
RN   [2] {ECO:0000312|EMBL:AFS68799.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Huang Z.G., Hong Q.N., Lun J.X., Lin W., Yang W., Deng Q.L., He Z.,
RA   Lai Y.X., Xing J.M., Liu Y.Q.;
RT   "Clone and bioinformatics analysis on the coding region of c20orf54 gene.";
RL   Submitted (AUG-2012) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Mammary gland, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5] {ECO:0000312|EMBL:EAX10658.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS LEU-267;
RP   MET-278 AND VAL-303.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION.
RX   PubMed=19122205; DOI=10.1093/jb/mvn181;
RA   Yamamoto S., Inoue K., Ohta K.Y., Fukatsu R., Maeda J.Y., Yoshida Y.,
RA   Yuasa H.;
RT   "Identification and functional characterization of rat riboflavin
RT   transporter 2.";
RL   J. Biochem. 145:437-443(2009).
RN   [8]
RP   FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=20463145; DOI=10.3945/jn.110.122911;
RA   Yao Y., Yonezawa A., Yoshimatsu H., Masuda S., Katsura T., Inui K.;
RT   "Identification and comparative functional characterization of a new human
RT   riboflavin transporter hRFT3 expressed in the brain.";
RL   J. Nutr. 140:1220-1226(2010).
RN   [9]
RP   SUBCELLULAR LOCATION, TOPOLOGY, DISULFIDE BOND, AND MUTAGENESIS OF CYS-326;
RP   CYS-386; ARG-455; CYS-463 AND CYS-467.
RX   PubMed=21512156; DOI=10.1152/ajpgi.00120.2011;
RA   Subramanian V.S., Rapp L., Marchant J.S., Said H.M.;
RT   "Role of cysteine residues in cell surface expression of the human
RT   riboflavin transporter-2 (hRFT2) in intestinal epithelial cells.";
RL   Am. J. Physiol. 301:G100-G109(2011).
RN   [10]
RP   INVOLVEMENT IN FALOND, INVOLVEMENT IN BVVLS1, AND VARIANT BVVLS1 ARG-17.
RX   PubMed=21110228; DOI=10.1007/s10545-010-9242-z;
RA   Bosch A.M., Abeling N.G., Ijlst L., Knoester H., van der Pol W.L.,
RA   Stroomer A.E., Wanders R.J., Visser G., Wijburg F.A., Duran M.,
RA   Waterham H.R.;
RT   "Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a
RT   riboflavin transporter defect mimicking mild MADD: a new inborn error of
RT   metabolism with potential treatment.";
RL   J. Inherit. Metab. Dis. 34:159-164(2011).
RN   [11]
RP   FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=24264046; DOI=10.1152/ajpgi.00349.2013;
RA   Yoshimatsu H., Yonezawa A., Yao Y., Sugano K., Nakagawa S., Omura T.,
RA   Matsubara K.;
RT   "Functional involvement of RFVT3/SLC52A3 in intestinal riboflavin
RT   absorption.";
RL   Am. J. Physiol. 306:G102-G110(2014).
RN   [12]
RP   VARIANTS BVVLS1 LYS-36; TRP-132; LEU-224; ALA-413 AND LEU-457, AND VARIANT
RP   MET-350.
RX   PubMed=20206331; DOI=10.1016/j.ajhg.2010.02.006;
RA   Green P., Wiseman M., Crow Y.J., Houlden H., Riphagen S., Lin J.P.,
RA   Raymond F.L., Childs A.M., Sheridan E., Edwards S., Josifova D.J.;
RT   "Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is
RT   caused by mutations in c20orf54.";
RL   Am. J. Hum. Genet. 86:485-489(2010).
RN   [13]
RP   VARIANTS BVVLS1 THR-28 AND LYS-71.
RX   PubMed=20920669; DOI=10.1016/j.ajhg.2010.05.021;
RA   Johnson J.O., Gibbs J.R., Van Maldergem L., Houlden H., Singleton A.B.;
RT   "Exome sequencing in Brown-Vialetto-van Laere syndrome.";
RL   Am. J. Hum. Genet. 87:567-569(2010).
RN   [14]
RP   VARIANTS BVVLS1 SER-21; HIS-220; VAL-312 AND ASP-375.
RX   PubMed=22718020; DOI=10.1038/jhg.2012.70;
RA   Dezfouli M.A., Yadegari S., Nafissi S., Elahi E.;
RT   "Four novel C20orf54 mutations identified in Brown-Vialetto-Van Laere
RT   syndrome patients.";
RL   J. Hum. Genet. 57:613-617(2012).
RN   [15]
RP   CHARACTERIZATION OF VARIANTS BVVLS1 ARG-17; THR-28; LYS-36; LYS-71 AND
RP   TRP-132, CHARACTERIZATION OF VARIANT MET-350, FUNCTION, TRANSPORTER
RP   ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=22273710; DOI=10.1016/j.ymgme.2011.12.021;
RA   Nabokina S.M., Subramanian V.S., Said H.M.;
RT   "Effect of clinical mutations on functionality of the human riboflavin
RT   transporter-2 (hRFT-2).";
RL   Mol. Genet. Metab. 105:652-657(2012).
RN   [16]
RP   VARIANTS BVVLS1 ASP-58; TRP-266; SER-319 AND ALA-413, AND VARIANT VAL-303.
RX   PubMed=22824638; DOI=10.1016/j.nmd.2012.05.007;
RA   Ciccolella M., Catteruccia M., Benedetti S., Moroni I., Uziel G.,
RA   Pantaleoni C., Chiapparini L., Bizzi A., D'Amico A., Fattori F.,
RA   Salsano M.L., Pastore A., Tozzi G., Piemonte F., Bertini E.;
RT   "Brown-Vialetto-van Laere and Fazio-Londe overlap syndromes: a clinical,
RT   biochemical and genetic study.";
RL   Neuromuscul. Disord. 22:1075-1082(2012).
RN   [17]
RP   VARIANT BVVLS1 VAL-330.
RX   PubMed=22633641; DOI=10.1016/j.pediatrneurol.2012.03.008;
RA   Koy A., Pillekamp F., Hoehn T., Waterham H., Klee D., Mayatepek E.,
RA   Assmann B.;
RT   "Brown-Vialetto-Van Laere syndrome: a riboflavin-unresponsive patient with
RT   a novel mutation in the C20orf54 gene.";
RL   Pediatr. Neurol. 46:407-409(2012).
RN   [18]
RP   VARIANT BVVLS1 SER-21, CHARACTERIZATION OF VARIANT BVVLS1 SER-21, FUNCTION,
RP   TRANSPORTER ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=27702554; DOI=10.1016/j.cca.2016.09.022;
RA   Udhayabanu T., Subramanian V.S., Teafatiller T., Gowda V.K., Raghavan V.S.,
RA   Varalakshmi P., Said H.M., Ashokkumar B.;
RT   "SLC52A2 [p.P141T] and SLC52A3 [p.N21S] causing Brown-Vialetto-Van Laere
RT   syndrome in an Indian patient: First genetically proven case with mutations
RT   in two riboflavin transporters.";
RL   Clin. Chim. Acta 462:210-214(2016).
CC   -!- FUNCTION: Plasma membrane transporter mediating the uptake by cells of
CC       the water soluble vitamin B2/riboflavin that plays a key role in
CC       biochemical oxidation-reduction reactions of the carbohydrate, lipid,
CC       and amino acid metabolism (PubMed:20463145, PubMed:22273710,
CC       PubMed:24264046, PubMed:27702554). Humans are unable to synthesize
CC       vitamin B2/riboflavin and must obtain it via intestinal absorption
CC       (PubMed:20463145). {ECO:0000269|PubMed:20463145,
CC       ECO:0000269|PubMed:22273710, ECO:0000269|PubMed:24264046,
CC       ECO:0000269|PubMed:27702554, ECO:0000303|PubMed:20463145}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=riboflavin(in) = riboflavin(out); Xref=Rhea:RHEA:35015,
CC         ChEBI:CHEBI:57986; Evidence={ECO:0000269|PubMed:20463145,
CC         ECO:0000269|PubMed:22273710, ECO:0000269|PubMed:24264046,
CC         ECO:0000269|PubMed:27702554};
CC   -!- ACTIVITY REGULATION: Activity is strongly inhibited by riboflavin
CC       analogs, such as lumiflavin, flavin mononucleotide (FMN), flavin
CC       adenine dinucleotide (FAD), by methylene blue, and to a lesser extent
CC       by amiloride. Riboflavin transport is Na(+)-independent at low pH but
CC       significantly reduced by Na(+) depletion under neutral pH conditions.
CC       {ECO:0000269|PubMed:20463145, ECO:0000269|PubMed:24264046}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.98 uM for riboflavin {ECO:0000269|PubMed:20463145};
CC   -!- INTERACTION:
CC       Q9NQ40; P54252: ATXN3; NbExp=3; IntAct=EBI-25845274, EBI-946046;
CC       Q9NQ40; P50570-2: DNM2; NbExp=3; IntAct=EBI-25845274, EBI-10968534;
CC       Q9NQ40; O14656-2: TOR1A; NbExp=3; IntAct=EBI-25845274, EBI-25847109;
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:20463145, ECO:0000269|PubMed:21512156,
CC       ECO:0000269|PubMed:24264046}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:20463145}. Cell membrane
CC       {ECO:0000269|PubMed:22273710, ECO:0000269|PubMed:27702554}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:29428966}; Multi-pass membrane protein
CC       {ECO:0000255}. Nucleus membrane {ECO:0000269|PubMed:29428966}; Multi-
CC       pass membrane protein. Cytoplasm {ECO:0000269|PubMed:29428966}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:29428966}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=SLC52A3a {ECO:0000303|PubMed:29428966};
CC         IsoId=Q9NQ40-1; Sequence=Displayed;
CC       Name=2; Synonyms=SLC52A3b {ECO:0000303|PubMed:29428966};
CC         IsoId=Q9NQ40-2; Sequence=VSP_003814, VSP_003815;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in testis. Highly expressed
CC       in small intestine and prostate. {ECO:0000269|PubMed:20463145}.
CC   -!- DISEASE: Brown-Vialetto-Van Laere syndrome 1 (BVVLS1) [MIM:211530]: A
CC       rare neurologic disorder characterized by sensorineural hearing loss
CC       and a variety of cranial nerve palsies, which develop over a relatively
CC       short period of time in a previously healthy individual. Sensorineural
CC       hearing loss may precede the neurological signs. The course is
CC       invariably progressive, but the rate of decline is variable within and
CC       between families. With disease evolution, long tract signs, lower motor
CC       neuron signs, cerebellar ataxia and lower cranial nerve (III-VI)
CC       palsies develop, giving rise to a complex picture resembling
CC       amyotrophic lateral sclerosis. Diaphragmatic weakness and respiratory
CC       compromise are some of the most distressing features, leading to
CC       recurrent chest infections and respiratory failure, which are often the
CC       cause of patients' demise. {ECO:0000269|PubMed:20206331,
CC       ECO:0000269|PubMed:20920669, ECO:0000269|PubMed:21110228,
CC       ECO:0000269|PubMed:22273710, ECO:0000269|PubMed:22633641,
CC       ECO:0000269|PubMed:22718020, ECO:0000269|PubMed:22824638,
CC       ECO:0000269|PubMed:27702554}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Fazio-Londe disease (FALOND) [MIM:211500]: A rare neurological
CC       disease characterized by progressive weakness of the muscles innervated
CC       by cranial nerves of the lower brain stem. It may present in childhood
CC       with severe neurological deterioration with hypotonia, respiratory
CC       insufficiency leading to premature death, or later in life with bulbar
CC       weakness which progresses to involve motor neurons throughout the
CC       neuroaxis. Clinical manifestations include dysarthria, dysphagia,
CC       facial weakness, tongue weakness, and fasciculations of the tongue and
CC       facial muscles. {ECO:0000269|PubMed:21110228}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the riboflavin transporter family.
CC       {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-5 is the initiator.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KY978478; AUI80409.1; -; mRNA.
DR   EMBL; KY978479; AUI80410.1; -; mRNA.
DR   EMBL; JX478249; AFS68799.1; -; mRNA.
DR   EMBL; AK074650; BAC11113.1; -; mRNA.
DR   EMBL; AK291706; BAF84395.1; -; mRNA.
DR   EMBL; AL118502; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10658.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10659.1; -; Genomic_DNA.
DR   EMBL; BC009750; AAH09750.2; -; mRNA.
DR   CCDS; CCDS13007.1; -. [Q9NQ40-1]
DR   RefSeq; NP_212134.3; NM_033409.3. [Q9NQ40-1]
DR   RefSeq; XP_005260712.1; XM_005260655.3.
DR   RefSeq; XP_011527450.1; XM_011529148.1.
DR   AlphaFoldDB; Q9NQ40; -.
DR   BioGRID; 125241; 1.
DR   IntAct; Q9NQ40; 3.
DR   STRING; 9606.ENSP00000217254; -.
DR   TCDB; 2.A.125.1.2; the eukaryotic riboflavin transporter (e-rft) family.
DR   GlyCosmos; Q9NQ40; 3 sites, 1 glycan.
DR   GlyGen; Q9NQ40; 4 sites, 2 O-linked glycans (2 sites).
DR   iPTMnet; Q9NQ40; -.
DR   PhosphoSitePlus; Q9NQ40; -.
DR   BioMuta; SLC52A3; -.
DR   DMDM; 82654931; -.
DR   MassIVE; Q9NQ40; -.
DR   PaxDb; Q9NQ40; -.
DR   PeptideAtlas; Q9NQ40; -.
DR   ProteomicsDB; 82078; -. [Q9NQ40-1]
DR   ProteomicsDB; 82079; -. [Q9NQ40-2]
DR   Antibodypedia; 54121; 85 antibodies from 15 providers.
DR   DNASU; 113278; -.
DR   Ensembl; ENST00000217254.11; ENSP00000217254.7; ENSG00000101276.18. [Q9NQ40-1]
DR   Ensembl; ENST00000381944.5; ENSP00000371370.3; ENSG00000101276.18. [Q9NQ40-2]
DR   Ensembl; ENST00000488495.3; ENSP00000494009.1; ENSG00000101276.18. [Q9NQ40-1]
DR   Ensembl; ENST00000645534.1; ENSP00000494193.1; ENSG00000101276.18. [Q9NQ40-1]
DR   GeneID; 113278; -.
DR   KEGG; hsa:113278; -.
DR   MANE-Select; ENST00000645534.1; ENSP00000494193.1; NM_033409.4; NP_212134.3.
DR   UCSC; uc002wed.5; human. [Q9NQ40-1]
DR   AGR; HGNC:16187; -.
DR   CTD; 113278; -.
DR   DisGeNET; 113278; -.
DR   GeneCards; SLC52A3; -.
DR   GeneReviews; SLC52A3; -.
DR   HGNC; HGNC:16187; SLC52A3.
DR   HPA; ENSG00000101276; Tissue enhanced (intestine, testis).
DR   MalaCards; SLC52A3; -.
DR   MIM; 211500; phenotype.
DR   MIM; 211530; phenotype.
DR   MIM; 613350; gene.
DR   neXtProt; NX_Q9NQ40; -.
DR   OpenTargets; ENSG00000101276; -.
DR   Orphanet; 572550; RFVT3-related riboflavin transporter deficiency.
DR   PharmGKB; PA25764; -.
DR   VEuPathDB; HostDB:ENSG00000101276; -.
DR   eggNOG; KOG4255; Eukaryota.
DR   GeneTree; ENSGT00390000003774; -.
DR   HOGENOM; CLU_034789_1_0_1; -.
DR   InParanoid; Q9NQ40; -.
DR   OMA; CGAAAQM; -.
DR   OrthoDB; 5477759at2759; -.
DR   PhylomeDB; Q9NQ40; -.
DR   TreeFam; TF314820; -.
DR   PathwayCommons; Q9NQ40; -.
DR   Reactome; R-HSA-196843; Vitamin B2 (riboflavin) metabolism.
DR   SignaLink; Q9NQ40; -.
DR   BioGRID-ORCS; 113278; 13 hits in 1149 CRISPR screens.
DR   ChiTaRS; SLC52A3; human.
DR   GeneWiki; C20orf54; -.
DR   GenomeRNAi; 113278; -.
DR   Pharos; Q9NQ40; Tbio.
DR   PRO; PR:Q9NQ40; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9NQ40; protein.
DR   Bgee; ENSG00000101276; Expressed in right testis and 117 other tissues.
DR   ExpressionAtlas; Q9NQ40; baseline and differential.
DR   Genevisible; Q9NQ40; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032217; F:riboflavin transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0006771; P:riboflavin metabolic process; TAS:Reactome.
DR   GO; GO:0032218; P:riboflavin transport; IDA:UniProtKB.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB.
DR   InterPro; IPR009357; Riboflavin_transptr.
DR   PANTHER; PTHR12929; SOLUTE CARRIER FAMILY 52; 1.
DR   PANTHER; PTHR12929:SF4; SOLUTE CARRIER FAMILY 52, RIBOFLAVIN TRANSPORTER, MEMBER 3; 1.
DR   Pfam; PF06237; DUF1011; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Cytoplasm; Deafness; Disease variant;
KW   Disulfide bond; Glycoprotein; Membrane; Nucleus; Phosphoprotein;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..469
FT                   /note="Solute carrier family 52, riboflavin transporter,
FT                   member 3"
FT                   /id="PRO_0000042636"
FT   TOPO_DOM        1..2
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3..23
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        24..43
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        44..64
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        65..71
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        72..92
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        93..97
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        98..118
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        119..137
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        138..158
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        159..220
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        221..241
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        242..292
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        293..313
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        314..335
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        336..356
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        357..359
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        360..380
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        381..396
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        397..417
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        418..427
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        428..448
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        449..469
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         251
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q4FZU9"
FT   CARBOHYD        94
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        168
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        386..463
FT                   /evidence="ECO:0000305|PubMed:21512156"
FT   VAR_SEQ         401..415
FT                   /note="ASWVLFSGCLSYVKV -> SIRPVGLLPLRTPHP (in isoform 2)"
FT                   /evidence="ECO:0000269|PubMed:29428966,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_003814"
FT   VAR_SEQ         416..469
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000269|PubMed:29428966,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_003815"
FT   VARIANT         17
FT                   /note="W -> R (in BVVLS1; loss of riboflavin transport; no
FT                   effect on localization to cell membrane; does not affect
FT                   protein abundance; dbSNP:rs797045190)"
FT                   /evidence="ECO:0000269|PubMed:21110228,
FT                   ECO:0000269|PubMed:22273710"
FT                   /id="VAR_077422"
FT   VARIANT         21
FT                   /note="N -> S (in BVVLS1; loss of localization to cell
FT                   membrane; loss of riboflavin transport; dbSNP:rs199588390)"
FT                   /evidence="ECO:0000269|PubMed:22718020,
FT                   ECO:0000269|PubMed:27702554"
FT                   /id="VAR_077423"
FT   VARIANT         28
FT                   /note="P -> T (in BVVLS1; loss of localization to cell
FT                   membrane; loss of riboflavin transport; does not affect
FT                   protein abundance; dbSNP:rs267606688)"
FT                   /evidence="ECO:0000269|PubMed:20920669,
FT                   ECO:0000269|PubMed:22273710"
FT                   /id="VAR_077424"
FT   VARIANT         36
FT                   /note="E -> K (in BVVLS1; loss of localization to cell
FT                   membrane; loss of riboflavin transport; does not affect
FT                   protein abundance; dbSNP:rs267606686)"
FT                   /evidence="ECO:0000269|PubMed:20206331,
FT                   ECO:0000269|PubMed:22273710"
FT                   /id="VAR_063694"
FT   VARIANT         58
FT                   /note="V -> D (in BVVLS1; dbSNP:rs797045192)"
FT                   /evidence="ECO:0000269|PubMed:22824638"
FT                   /id="VAR_077425"
FT   VARIANT         71
FT                   /note="E -> K (in BVVLS1; loss of localization to cell
FT                   membrane; loss of riboflavin transport; does not affect
FT                   protein abundance; dbSNP:rs267606683)"
FT                   /evidence="ECO:0000269|PubMed:20920669,
FT                   ECO:0000269|PubMed:22273710"
FT                   /id="VAR_077426"
FT   VARIANT         74
FT                   /note="I -> M (in dbSNP:rs35655964)"
FT                   /id="VAR_053565"
FT   VARIANT         132
FT                   /note="R -> W (in BVVLS1; loss of localization to cell
FT                   membrane; loss of riboflavin transport; does not affect
FT                   protein abundance; dbSNP:rs267606684)"
FT                   /evidence="ECO:0000269|PubMed:20206331,
FT                   ECO:0000269|PubMed:22273710"
FT                   /id="VAR_063695"
FT   VARIANT         174
FT                   /note="D -> G (in dbSNP:rs6054614)"
FT                   /id="VAR_053566"
FT   VARIANT         220
FT                   /note="P -> H (in BVVLS1; unknown pathological
FT                   significance; dbSNP:rs797045194)"
FT                   /evidence="ECO:0000269|PubMed:22718020"
FT                   /id="VAR_077427"
FT   VARIANT         224
FT                   /note="F -> L (in BVVLS1; dbSNP:rs267606685)"
FT                   /evidence="ECO:0000269|PubMed:20206331"
FT                   /id="VAR_063696"
FT   VARIANT         266
FT                   /note="R -> W (in BVVLS1; unknown pathological
FT                   significance; dbSNP:rs370499474)"
FT                   /evidence="ECO:0000269|PubMed:22824638"
FT                   /id="VAR_077428"
FT   VARIANT         267
FT                   /note="P -> L (in dbSNP:rs3746804)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_053567"
FT   VARIANT         278
FT                   /note="T -> M (in dbSNP:rs3746803)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_053568"
FT   VARIANT         303
FT                   /note="I -> V (in dbSNP:rs3746802)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:22824638"
FT                   /id="VAR_053569"
FT   VARIANT         312
FT                   /note="A -> V (in BVVLS1; unknown pathological
FT                   significance; dbSNP:rs752218005)"
FT                   /evidence="ECO:0000269|PubMed:22718020"
FT                   /id="VAR_077429"
FT   VARIANT         319
FT                   /note="P -> S (in BVVLS1; unknown pathological
FT                   significance; dbSNP:rs797045195)"
FT                   /evidence="ECO:0000269|PubMed:22824638"
FT                   /id="VAR_077430"
FT   VARIANT         330
FT                   /note="G -> V (in BVVLS1; unknown pathological
FT                   significance; dbSNP:rs797045196)"
FT                   /evidence="ECO:0000269|PubMed:22633641"
FT                   /id="VAR_077431"
FT   VARIANT         350
FT                   /note="L -> M (no effect on riboflavin transport; no effect
FT                   on localization to cell membrane; dbSNP:rs76947760)"
FT                   /evidence="ECO:0000269|PubMed:20206331,
FT                   ECO:0000269|PubMed:22273710"
FT                   /id="VAR_063698"
FT   VARIANT         375
FT                   /note="G -> D (in BVVLS1; unknown pathological
FT                   significance; dbSNP:rs1219868273)"
FT                   /evidence="ECO:0000269|PubMed:22718020"
FT                   /id="VAR_077432"
FT   VARIANT         411
FT                   /note="S -> R (in dbSNP:rs910857)"
FT                   /id="VAR_063699"
FT   VARIANT         413
FT                   /note="V -> A (in BVVLS1; dbSNP:rs267606687)"
FT                   /evidence="ECO:0000269|PubMed:20206331,
FT                   ECO:0000269|PubMed:22824638"
FT                   /id="VAR_063700"
FT   VARIANT         457
FT                   /note="F -> L (in BVVLS1; dbSNP:rs779750163)"
FT                   /evidence="ECO:0000269|PubMed:20206331"
FT                   /id="VAR_063701"
FT   MUTAGEN         326
FT                   /note="C->A: No effect on cell surface localization."
FT                   /evidence="ECO:0000269|PubMed:21512156"
FT   MUTAGEN         386
FT                   /note="C->A: Abolishes cell surface localization."
FT                   /evidence="ECO:0000269|PubMed:21512156"
FT   MUTAGEN         455
FT                   /note="R->A: No effect on cell surface localization."
FT                   /evidence="ECO:0000269|PubMed:21512156"
FT   MUTAGEN         463
FT                   /note="C->A: Abolishes cell surface localization."
FT                   /evidence="ECO:0000269|PubMed:21512156"
FT   MUTAGEN         467
FT                   /note="C->A: Abolishes cell surface localization."
FT                   /evidence="ECO:0000269|PubMed:21512156"
FT   CONFLICT        11
FT                   /note="V -> D (in Ref. 3; BAF84395)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        199
FT                   /note="L -> P (in Ref. 3; BAC11113)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   469 AA;  50805 MW;  239ED67348C93739 CRC64;
     MAFLMHLLVC VFGMGSWVTI NGLWVELPLL VMELPEGWYL PSYLTVVIQL ANIGPLLVTL
     LHHFRPSCLS EVPIIFTLLG VGTVTCIIFA FLWNMTSWVL DGHHSIAFLV LTFFLALVDC
     TSSVTFLPFM SRLPTYYLTT FFVGEGLSGL LPALVALAQG SGLTTCVNVT EISDSVPSPV
     PTRETDIAQG VPRALVSALP GMEAPLSHLE SRYLPAHFSP LVFFLLLSIM MACCLVAFFV
     LQRQPRCWEA SVEDLLNDQV TLHSIRPREE NDLGPAGTVD SSQGQGYLEE KAAPCCPAHL
     AFIYTLVAFV NALTNGMLPS VQTYSCLSYG PVAYHLAATL SIVANPLASL VSMFLPNRSL
     LFLGVLSVLG TCFGGYNMAM AVMSPCPLLQ GHWGGEVLIV ASWVLFSGCL SYVKVMLGVV
     LRDLSRSALL WCGAAVQLGS LLGALLMFPL VNVLRLFSSA DFCNLHCPA
//
